A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.
AffiliationCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
Abstract159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1, 3, 5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P = 0.0007), and less nausea and vomiting (P = 0.03).
CitationA randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. 1991, 117 Suppl 4:S139-40 J. Cancer Res. Clin. Oncol.
JournalJournal of Cancer Research and Clinical Oncology
- A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.
- Authors: Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L
- Issue date: 1993 Jun
- Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
- Authors: Skubitz KM, Hamdan H, Thompson RC Jr
- Issue date: 1993 Nov 15
- Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
- Authors: Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK
- Issue date: 1998 Jan 15
- A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
- Authors: Evans WK, Stewart D, Logan D, Maroun J, Goss G, Shepherd FA, Latreille J, Warner E, Dahrouge S
- Issue date: 1992 Dec
- The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
- Authors: Cantwell BM, Bozzino JM, Corris P, Harris AL
- Issue date: 1988 Feb